Amantadine therapy for fatigue in multiple sclerosis

Can J Neurol Sci. 1985 Aug;12(3):251-4. doi: 10.1017/s0317167100047107.


We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo. On amantadine 31% had marked improvement; 15.6% moderate improvement; 15.6% mild improvement; and 36.5% unchanged. On placebo, none noted marked improvement; one claimed moderate improvement on either amantadine or placebo. 18.7% reported mild improvement on placebo; and most of them had similar or more response to amantadine. No patient selected placebo over amantadine at the end of the trial. Overall improvement was seen in 62.5% of patients on amantadine and 21.8% on placebo. Additional experience up to two years suggests continued benefit but common and important side-effects.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Amantadine / adverse effects
  • Amantadine / therapeutic use*
  • Clinical Trials as Topic
  • Fatigue / drug therapy*
  • Fatigue / etiology
  • Fatigue / physiopathology
  • Humans
  • Multiple Sclerosis / complications*


  • Amantadine